Expansion into Spatial Genomics
Takara Bio USA Holdings, Inc. (TBUSH), a subsidiary of the global biotechnology leader Takara Bio Inc., has announced its acquisition of Curio Bioscience, a pioneer in spatial genomics. This strategic move aims to expand Takara Bio’s already extensive single-cell genomics portfolio by integrating cutting-edge spatial biology technologies. TBUSH, part of the global Takara Bio Group, supports scientists in discovery, translational, and clinical research. The acquisition of Curio Bioscience is expected to significantly enhance Takara Bio’s capabilities, providing customers with deeper insights into tissue spatial organization and molecular composition.
Innovative Technologies Driving Research
Curio Bioscience brings its advanced Trekker and Seeker technologies into the fold, which are designed to integrate spatial information with molecular data. This integration allows researchers to transform single-cell sequencing data into spatially resolved maps, offering unprecedented high-resolution insights into cellular organization within their native tissue environments. “Curio’s dedication to innovative approaches, such as mapping the entire transcriptome with unparalleled sensitivity, aligns perfectly with our mission,” said Carol Lou, President and CEO of Takara Bio USA. The combination of Curio’s technology with Takara Bio’s robust NGS and single-cell toolset promises to deliver industry-leading solutions for spatial biology applications.
Solidifying Leadership in Single-Cell Genomics
With the addition of Curio’s technologies, Takara Bio is poised to further solidify its leadership in the single-cell genomics market. The company’s continuous drive for innovation supports a wide range of research applications, including cancer biology, neuroscience, developmental biology, and immunology. Advisors for the acquisition included Houlihan Lokey and Cooley LLP for Takara Bio, and Aquilo Partners, L.P. and Dorsey & Whitney LLP for Curio Bioscience. Takara Bio’s ongoing commitment to enhancing life sciences research and improving global health outcomes is underscored by this strategic acquisition, which aligns with their vision of advancing biotechnology solutions for disease prevention and quality of life improvements.
